Catheter-based renal denervation for refractory hypertension: A review of the literature

Journal of the Indian Medical Association

Volumn 110, Issue 5, 2012, Pages 292-296

  Bertog, Stefan ^a   Schultz, Jason C ^b   Franke, Jennifer ^c   Hoffman, Ilona ^c   Sievert, Horst ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c CardioVascular Center Frankfurt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTERY CATHETER; ARTERY DISSECTION; ARTICLE; BLOOD PRESSURE; CATHETER ABLATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FALSE ANEURYSM; FEMORAL ARTERY PSEUDOANEURYSM; HIGH SODIUM INTAKE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; RADIOFREQUENCY ABLATION; RENAL ARTERY DISSECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYMPATHECTOMY; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 84863747898     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Fergusen B, Flegal K, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21-181.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
4. Cuspidi C, Macca G, Sampieri L, Michev I, Saleruo M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-70.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
6. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003; 361: 1629-41.
7. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584-94.
8. Rettig R. Does the kidney play a role in the aetiology of primary hypertension? Evidence from renal transplantation studies in rats and humans. J Hum Hypertens 1993; 7: 177-80.
9. Cowley AW Jr. Long-term control of arterial blood pressure. Physiol Rev 1992; 72: 231-300.
10. Roman RJ, Cowley AW Jr. Characterization of a new model for the study of pressure-natriuresis in the rat. Am J Physiol 1985; 248: F190-8.
11. Bernard C. Lecons sur les Proprietes et les Alterations Pathologiques des Liquides de l'Organisme. Bailliers et Fils 1859; 2: 170-1.
12. Aperia A, Ibarra F, Svensson LB, Klee C, Greengard P. Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells. Proc Natl Acad Sci U S A 1992; 89: 7394-7.
13. Skott O, Jensen BL. Cellular and intrarenal control of rennin secretion. Clin Sci 1993; 84: 1-10.
14. Ciriello J, de Oliveira CV. Renal afferents and hypertension. Curr Hypertens Rep 2002; 4: 136-42.
15. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15: 717-24.
16. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-82.
17. Abramczyk P, Zwolinska A, Oficjalski P, Przybylski J. Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1999; 26: 32-4.
18. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-7.
19. Peet MM, Isberg EM. The surgical treatment of essential hypertension. JAMA 1946; 130: 467-73.
20. Evelyn KA, Alexander F, Cooper SR. Effect of sympathectomy on blood pressure in hypertension: a review of 13 years' experience of the Massachusetts General Hospital. JAMA 1949; 140: 592-602.
21. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8.
22. Smith HW. Hypertension and urologic disease. Am J Med 1948; 4: 724-43.
23. McHugh MI, Tanboga H, Marcen R, Liano F, Robson V, Wilkinson R. Hypertension following renal transplantation: the role of the host's kidney. QJM 1980; 49: 395-403.
24. Huysmans FT, van Heusden FH, Wetzels JF, Hoitsma AJ, Koene RA. Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys. Transplantation 1988; 46: 234-7.
25. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dajkhorstoei Lt, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
26. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension 1983; 5: 86-99.
27. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 1989; 14: 177-83.
28. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadouski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
29. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-7.
30. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
31. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-4.
32. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci 1994; 87: 13-20.
33. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615-21.
34. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.
35. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.